RxDoctor Payments Data

Bradford West, MD

Nephrology · Springfield, ILNPI 1194969170

Payments from drug & device makers

$5,105in general payments, 2019–2025

Across 64 payments — averaging $79.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$3K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$748
  • Amgen$310
  • AstraZeneca$287
  • Takeda Pharmaceuticals U.S.A., Inc.$143
  • Novartis$104
  • plus $563 from 15 others

What the payments were for

  • Consulting fees$3,13061%
  • Travel & lodging$1663%
  • Food & beverage$1,50229%
  • Education$3096%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,105 in reported general payments places this provider in the 80th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$196,580
Medicare patients
546
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cinacalcet Hcl89$59,728
VelphoroSucroferric Oxyhydroxide13$56,134
FarxigaDapagliflozin Propanediol59$54,020
EliquisApixaban75$46,095
AuryxiaFerric Citrate20$29,074
JardianceEmpagliflozin27$26,421
Nifedipine ErNifedipine281$15,378
Valganciclovir Hcl54$15,140
Potassium Citrate ErPotassium Citrate84$6,973
Tacrolimus44$6,071
Sevelamer Carbonate22$5,960
Potassium Chloride196$5,709
Calcitriol348$4,995
LokelmaSodium Zirconium Cyclosilicate18$4,811
Pravastatin Sodium243$2,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$287$58,83077 claims
Fresenius USA Marketing, Inc.Velphoro$19$56,13413 claims
Boehringer IngelheimJardiance$34$26,42127 claims
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$748$1,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 524 nephrology providers in Illinois.

Other nephrology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →